July 2025
The global cell therapy market size was accounted for USD 6.04 billion in 2024 and is anticipated to reach around USD 47.72 billion by 2034, growing at a CAGR of 22.96% from 2025 to 2034.
The U.S. cell therapy market size was evaluated at USD 3.39 billion in 2024 and is predicted to be worth around USD 27.12 billion by 2034, rising at a CAGR of 23.11% from 2025 to 2034.
North America dominated the global cell therapy market with the largest market share of 59% in 2024. Factors such as rising incidents of chronic disorders and growing investments for the development of cell therapy market in the U.S. Cellino Biotech, an autonomous cell treatment manufacturing firm obtained a first investment round of $80 million in January 2022. Cellino wants to make stem cell-based medicines more accessible with the goal of building the first self-contained human cell foundry by 2025. In addition, the cell therapy market in North America region is also being driven by growing applications of stem cell technologies for the treatment of various diseases. Moreover, the growing research and development activities are boosting the growth of North America cell therapy market.
Asia-Pacific is expected to develop at the fastest growth rate 16% during the forecast period. China dominates the cell therapy market in Asia-Pacific region. The favorable government regulations are contributing towards the growth of cell therapy market in this region. Asia-Pacific has a great potential for market expansion, as it accounted for roughly 4.6 billion of the world human population in 2019, which might act as a prospective patient base. Furthermore, emerging nations such as China and India are predicted to grow as a result of improved healthcare facilities, low cost, and increased knowledge of cell therapy.
U.S. Cell Therapy Market Trends
The U.S. has seen a steady growth in the cell therapy market, the growth is driven by the increased demand for personalized medicine according to patients' needs, and improvement in treatment accuracy due to which drives the growth of the market in the country. Advanced manufacturing techniques for efficiency and scaling production, and making it accessible for the patients and the population due to advancements, drive the growth in the U.S.
Groundbreaking research and clinical trials related to cell-based therapies fuel the growth of the market. Advances in immunotherapy and the fight for diseases and the immune system contribute to the growth and expansion of the market in the country.
India Cell Therapy Market Trends
The growing medical sector and improvements and innovations in the country boost the growth of the market. Rising ethical considerations and regulatory guidelines in the country promote the focus on cell therapy technology with advances by technological advancement in the field, like integration of artificial intelligence (AI) and machine learning, as they help in accuracy and precision. These applications boost the growth of the market and help in the expansion of the country.
What are the Latest Trends in Cell Therapy Market?
The growth of global cell therapy market is attributed to the rising incidents of chronic disorders and infections. In addition, the growing cases of diabetes are also boosting the market growth. As per the International Diabetes Federation Diabetes Altas, almost 573 million persons globally had diabetes in 2022, with the number anticipated to grow by 643 million by 2033 and 783 million by 2045. Moreover, the growing number of research studies and clinical trials are also boosting the growth of global cell therapy market.
One of the key factors propelling the expansion of global cell therapy market is adoption of innovative and latest technologies. Furthermore, after the impact of COVID-19 pandemic, the market for cell therapy is growing at a rapid pace. With over 900 companies working on advanced therapeutics around the world and around 1,000 cell or gene therapy clinical studies now conducted, the cell therapy market might see a surge in number of approvals. According to industry experts, up to 60 new cell therapies could be developed in the next few years, curing around 350,000 patients in the U.S. alone.
The impact of the COVID-19 pandemic on the growth of global cell therapy market is positive in nature. Due to pandemic, the cell therapies got momentum in the market. For example, Calidi Biotherapeutics Inc. announced in April 2020 that the FDA had approved the Investigational New Drug application approved by its partner, Personalized Stem Cells Inc. for the diagnosis and treatment of COVID-19 patients using stem cell therapy. Thus, this had positive outlook on the cell therapy market growth.
The global cell therapy market is also expanding due to stringent government regulations and guidelines. In addition, the growing investments for expansion of cell therapy market are paving way for the development of global cell therapy market. In July 2019, Bayer invested $215 million in Century Therapeutics, a biotechnology business established in the U.S. that aims to develop medicines for solid tumors and blood cancer. A $35 million donation from Versant Ventures and Fujifilm Cellular Dynamics boosted funding to $250 billion which is expected to help the sector to develop even more.
The government all around the world is constantly investing for the development of biopharmaceutical industry. This is directly impacting the growth of global cell therapy market. The key market players are collaborating with government agencies for the introduction of new cell therapies in the global market. In addition, market players are targeting developed and developing regions for the growth and development of global cell therapy market.
On the other hand, the high cost of cell therapies is a major challenge for the expansion of global cell therapy market. Moreover, lack of skilled professionals also acts as restraint for the cell therapy market growth. However, the growth of global cell therapy market is expected in near future due to wide applications of cell therapy.
| Report Coverage | Details |
| Growth Rate from 2025 to 2034 | CAGR of 22.96% |
| Market Size in 2025 | USD 7.43 Billion |
| Market Size by 2034 | USD 47.72 Billion |
| Largest Market | North America |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Use Type, Therapy Type, End User, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
The research use segment led the global market in 2024. Cell therapy is widely used for research purposes. The growing research and development initiatives are driving the growth of the segment. In addition, key market players are highly investing in research projects. Not only market players are investing in research projects but also government agencies are collaborating for cell-based research projects. All of these factors are driving the growth of the segment.
The clinical use segment is expected to grow at a notable CAGR during the forecast period. Cell therapy is largely used for the treatment and diagnostics in some therapeutic areas such as malignancies, musculoskeletal therapies, autoimmune disorders, and dermatology. Thus, the growing number of clinical trials is boosting the segment’s growth.
The autologous cell therapy segment held the largest share of 58.30% in the 2024 global cell therapy market. In the autologous cell therapy patient’s own cells are used for treatment, controlling immune rejection and promoting personalized medicine. The segment is essential for burns, bone repair, cartilage damage, and blood cancers (CAR-T) conditions. The development in this therapy type is steered by regulatory approvals and rising demands. The segment also faces challenges, but the advancement in continuous production techniques and scaled-out manufacturing is developing rapidly to reach the massive number of treatments and clinical trials.
The allogenic therapies segment is projected to grow at a solid CAGR during the forecast period. The segment is growing due to increasing research and development activities. Moreover, market players are adopting unique strategies for segment growth. For example, SpringWorks and Allogene Therapeutics Inc. signed a clinical trial partnership agreement in January 2020 for the investigation of ALLO-715 in patients with multiple myeloma who are also taking Nirogacestat.
The stem cells segment held the largest share of 65.70% in the 2024 global cell therapy market. The stem cells' potency to differentiate and self-renew into a mature cell is steering the global cell therapy. The segment provides treatments for degenerative disease via regenerative medicine that repairs tissue and also introduces tools for drug discovery. The major developments mainly focus on advancing the ability to provide stem cells effectively. Apart from this, the use of nanotechnology and the production of induced pluripotent stem cells (iPSCs) improve safety and precision. Other productions are mesenchymal, embryonic, and hematopoietic stem cells.
The non-stem cells segment is expected to grow at a CAGR of 12.40% during the forecast period. The non-stem cells segment is also emerging with its immune modulation for numerous diseases and the targeted cellular replacement. The global cell therapy includes immune cells like NK, dendritic, and T cells, and other somatic cells, such as chondrocytes are established from the isolated human cells, extended, and later provided to patients for the treatment. Beta cells are essential, acting as an epicenter for recovery from diabetes, and fibroblasts are crucial as a significant cell source for cell therapy.
The bone marrow segment held the largest share of 34.60% in the 2024 global cell therapy market. The bone marrow cells, mesenchymal stem cells (MSCs), and hematopoietic stem cells (HSCs) are a complex source for cell therapy. MSCs have the capability in regenerative medicine with their differentiation into numerous cell types, and HSCs help in the restoration of the immune and blood systems after transplantation, especially for blood cancers. The development in bone-marrow-based cell therapies has accelerated, with its early transplantation shifting to critical regenerative treatments with the rapid contribution of the global infrastructure.
The engineered/genetically modified cells segment is expected to rise at a CAGR of 14.20% during the forecast period. The segment in cell therapy is gaining traction with its genetic material from a donor cell. With viral or non-viral vector method, the modification takes place to provide therapeutic genes and enable potential roles in major diseases such s cancer, by monitoring the immune system and introducing regeneration. The development of genetically modified cells in global cell therapy is encompassed by the approved treatments, such as CAR-T cells for blood cancer, and their continuous research in regenerative medicine applications, like tissue repair.
The viral vector technology segment held the largest share of 36.90% in the 2024 global cell therapy market. The viral vector technology plays a crucial role in global cell therapy by serving as a delivery source to make genetic material reachable from one end to specific cells, providing treatments for numerous cancers, genetic disorders, and other diseases. The ongoing development of this technology has enhanced vector efficiency, potency, and safety to focus on specific cells that will lead to an increase in approved therapies. The major vectors, such as lentivirus (LV) and adeno-associated virus (AAV), have been introduced to overcome certain challenges.
The gene editing tools segment is expected to grow at a CAGR of 15.10% during the forecast period. The gene editing tools, such as ZFNs, CRISPR-Cas9, and TALENs, are crucial in cell therapy for implementing accurate and important changes to DNA, delivering the development of advanced treatments for cancer and genetic disorders. The tools enable modification of patient cells to set accurate mutations that improve immune responses against the cancer or introduce universal cell therapies by editing donor cells to avoid rejection. The technological development, mainly in CRISPR-Cas9, has leveraged the segment.
The oncology segment held the largest share of 43.80% in the 2024 global cell therapy market. In oncology, cell therapy uses modified immune cells, such as stem cells and CAR-T cells, to fight and end cancer cells. The rising hematologic cancers (eg, Lymphoma, myeloma, leukemia) and solid tumors (eg, melanoma, lung cancer, glioblastoma) have largely contributed to the growth of the global cell therapy. Additionally, the development aims to discover more effective and personalized treatments for solid and blood tumors by designing cells for specific scenarios and discovering new types of cells, such as NK cells.
The neurological disorders segment is expected to rise at a CAGR of 13.50% during the forecast period. The cell therapy carries a transitioning ability for neurological disorders such as stroke, spinal cord injury, parkinson’s, and Alzheimer's disease, with its replacement potency of the damaged cells and revealing the protective factors. The developed mesenchymal stem cells (MSCs) and induced pluripotent stem cells (IPSCs) are major cell types enabling different cell sourcing and scalability. These pave the way for cell therapy’s advancement concerning the rising neurological disorders.
The hospitals and clinics segment held the largest share of 40.20% in the 2024 global cell therapy market. The hospitals and clinics are largely adopting cell therapy to their portfolio to meet the advanced needs of treatment and the demand for precision therapy. The segment is an epicenter of global cell therapy development. The patient enrollment in clinical trials needs clinics, and the storage/receiving of finished cell products requires hospital space. Wherein the academic medical centers have potentially pioneered these therapies. The vast infrastructure development is essential in all medical centers for endless processes like shipment, storage, collection, infusion, and preservation to further succeed in covering use and patient reach.
The biopharmaceutical and biotechnology company segment is expected to grow at a CAGR of 12.80% during the forecast period. The biopharmaceutical and biotechnology companies are at the center of the evolution of cell therapy, empowering innovation via advancements such as engineered cell production and CRISPR gene editing. The segment has targeted personalized treatment of diseases and accelerated scaling and manufacturing of the critical therapies. The key role of these companies involves significant investment in R&D, collaboration with emerging firms, and addressing challenges related to accessibility and cost to broaden the availability of effective treatments for patients worldwide.
By Therapy Type
By Cell Type
By Cell Source
By Technology / Manufacturing Platform
By Application
By End User
By Geography
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
July 2025
January 2025
January 2025
January 2025